Robecosam AG reduced its position in shares of UnitedHealth Group (NYSE:UNH) by 15.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 73,817 shares of the healthcare conglomerate’s stock after selling 13,160 shares during the quarter. Robecosam AG’s holdings in UnitedHealth Group were worth $16,444,000 at the end of the most recent quarter.
Other large investors have also recently made changes to their positions in the company. Aevitas Wealth Management Inc. purchased a new position in shares of UnitedHealth Group during the 4th quarter valued at $102,000. Exane Derivatives grew its holdings in shares of UnitedHealth Group by 15,333.3% during the 4th quarter. Exane Derivatives now owns 463 shares of the healthcare conglomerate’s stock valued at $102,000 after acquiring an additional 460 shares in the last quarter. Pathstone Family Office LLC purchased a new position in shares of UnitedHealth Group during the 4th quarter valued at $129,000. Trustcore Financial Services LLC purchased a new position in shares of UnitedHealth Group during the 4th quarter valued at $133,000. Finally, Baystate Wealth Management LLC grew its holdings in shares of UnitedHealth Group by 64.9% during the 4th quarter. Baystate Wealth Management LLC now owns 762 shares of the healthcare conglomerate’s stock valued at $186,000 after acquiring an additional 300 shares in the last quarter. 86.73% of the stock is currently owned by institutional investors.
UNH has been the topic of several research analyst reports. Goldman Sachs initiated coverage on shares of UnitedHealth Group in a report on Wednesday, January 3rd. They set a “buy” rating and a $269.00 price target on the stock. Credit Suisse Group restated a “buy” rating on shares of UnitedHealth Group in a report on Wednesday, December 27th. Cantor Fitzgerald restated a “buy” rating and set a $235.00 price target on shares of UnitedHealth Group in a report on Monday, December 25th. Deutsche Bank upped their price objective on shares of UnitedHealth Group to $260.00 and gave the stock a “buy” rating in a report on Wednesday, January 17th. Finally, Citigroup upped their price objective on shares of UnitedHealth Group from $235.00 to $268.00 and gave the stock a “buy” rating in a report on Wednesday, January 17th. Three analysts have rated the stock with a hold rating and twenty-six have assigned a buy rating to the stock. UnitedHealth Group currently has an average rating of “Buy” and a consensus price target of $251.13.
UnitedHealth Group stock opened at $234.34 on Tuesday. The firm has a market cap of $227,458.84, a price-to-earnings ratio of 23.27, a PEG ratio of 1.36 and a beta of 0.77. The company has a debt-to-equity ratio of 0.56, a current ratio of 0.71 and a quick ratio of 0.73. UnitedHealth Group has a fifty-two week low of $166.65 and a fifty-two week high of $250.79.
UnitedHealth Group (NYSE:UNH) last released its earnings results on Tuesday, April 17th. The healthcare conglomerate reported $3.04 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.91 by $0.13. The firm had revenue of $55.19 billion during the quarter, compared to analyst estimates of $54.90 billion. UnitedHealth Group had a net margin of 5.41% and a return on equity of 22.06%. The business’s revenue was up 13.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.37 EPS. equities analysts forecast that UnitedHealth Group will post 12.61 earnings per share for the current fiscal year.
In other news, insider Larry C. Renfro sold 22,184 shares of the company’s stock in a transaction dated Thursday, March 15th. The shares were sold at an average price of $228.94, for a total transaction of $5,078,804.96. Following the completion of the transaction, the insider now owns 173,229 shares of the company’s stock, valued at $39,659,047.26. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Michele J. Hooper sold 10,000 shares of the company’s stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $237.76, for a total transaction of $2,377,600.00. Following the transaction, the director now directly owns 37,284 shares of the company’s stock, valued at approximately $8,864,643.84. The disclosure for this sale can be found here. In the last three months, insiders have sold 67,019 shares of company stock valued at $15,415,333. Company insiders own 0.89% of the company’s stock.
WARNING: This news story was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another site, it was illegally copied and reposted in violation of US & international copyright and trademark law. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/24/unitedhealth-group-unh-holdings-cut-by-robecosam-ag.html.
UnitedHealth Group Profile
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older, addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; and Medicaid plans, Children's Health Insurance Program, and health care programs; and health and dental benefits.
Receive News & Ratings for UnitedHealth Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group and related companies with MarketBeat.com's FREE daily email newsletter.